Fingolimod Hydrochloride

CAS 162359-56-0 21 current recordsSmall Molecule

Who holds supplier records for Fingolimod Hydrochloride? 21 organisations hold a current record for Fingolimod Hydrochloride: an active US FDA Type II Drug Master File or a CEP. 15 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (13), Netherlands (2), Argentina (1), China (1) and 1 other country (1); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Fingolimod Hydrochloride: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/fingolimod-hydrochloride

Reading the evidence

  • 21 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    13 of the 18 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 12 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Fingolimod Hydrochloride expires 30 Sept 2032. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (21)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Fingolimod Hydrochloride. Country is the organisation's recorded country, not necessarily the manufacturing site.

India13Netherlands2Argentina1China1Türkiye1Country not recorded for 3
Need Fingolimod Hydrochloride sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (15)

Certificates of Suitability on the EDQM register for Fingolimod Hydrochloride, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 17 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
MAPRIMED S.A. Buenos AiresAR
CEP 2020-312 - Rev 02
Fingolimod hydrochloride
Sept 2026Inspected Jul 2025
France
BIOCON LIMITED BengaluruIN
CEP 2020-156 - Rev 03
Fingolimod hydrochloride, Form-I
Aug 2026—
HONOUR LAB LIMITED HyderabadIN
CEP 2019-171 - Rev 02
Fingolimod hydrochloride
Aug 2026—
MATRIX PHARMACORP PRIVATE LIMITED SangareddyIN
CEP 2019-076 - Rev 05
Fingolimod hydrochloride
Jul 2026—
EMCURE PHARMACEUTICALS LIMITED PuneIN
CEP 2022-413 - Rev 01
Fingolimod hydrochloride
Jun 2026—
INTAS PHARMACEUTICALS LIMITED AhmedabadIN
CEP 2020-090 - Rev 03
Fingolimod hydrochloride, Form-I, micronised
May 2026—
ALIVUS LIFE SCIENCES LIMITED MumbaiIN
CEP 2020-108 - Rev 02
Fingolimod hydrochloride
May 2026—
SYNTHON B.V. NijmegenNL
CEP 2020-220 - Rev 01
Fingolimod hydrochloride
Mar 2026Inspected May 2024
Netherlands
RUYUAN HEC PHARM CO., LTD. ShaoguanCN
CEP 2019-140 - Rev 02
Fingolimod hydrochloride, Form-I
Mar 2026—
TAPI NL B.V. AmsterdamNL
CEP 2018-259 - Rev 05
Fingolimod hydrochloride
Mar 2025—
DR. REDDY'S LABORATORIES LIMITED HyderabadIN
CEP 2022-164 - Rev 00
Fingolimod hydrochloride, Form-I
Oct 2024—
ALEMBIC PHARMACEUTICALS LIMITED VadodaraIN
CEP 2019-301 - Rev 02
Fingolimod hydrochloride
Jun 2024—
MSN LABORATORIES PRIVATE LIMITED Kardanur VillageIN
R0-CEP 2021-066 - Rev 01
Fingolimod hydrochloride, Form-I
Aug 2023—
SHILPA PHARMA LIFESCIENCES LIMITED RaichurIN
R0-CEP 2019-145 - Rev 01
Fingolimod hydrochloride
Jul 2022—
Deva Holding A.Ş. IstanbulTR
R0-CEP 2020-352 - Rev 00
Fingolimod hydrochloride
May 2022—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (17 listed products contain Fingolimod Hydrochloride). The latest listed patent expires 30 Sept 2032. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Fingolimod Hydrochloride is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL544665).

Chemical identity

IUPAC name
2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride
Canonical SMILES
CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl
InChIKey
SWZTYAVBMYWFGS-UHFFFAOYSA-N
Synonyms
Fingolimod, Fingolimod accord, Fingolimod (as hydrochloride), Fingolimod hcl, Fingolimod hydrochlorid, Fingolimod hydrochloride, Fingolimod mylan, FTY720, FTY-720 HYDROCHLORIDE, FTY720 HYDROCHLORIDE, Gilenia, Gilenya

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Sphingosine 1-phosphate Receptor Modulator
Mechanism of action
Sphingosine 1-Phosphate Receptor Modulators

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Fingolimod Hydrochloride?

21 organisations hold an active US FDA Type II Drug Master File or a CEP for Fingolimod Hydrochloride: MSN Laboratories Private Limited (India), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), Biocon Limited (India), Emcure Pharmaceuticals Limited (India), HONOUR LAB LTD (India), Intas Pharmaceuticals Ltd. (India) and MAPRIMED SA (Argentina), and 13 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Fingolimod Hydrochloride Drug Master Files are active?

MSN Laboratories Private Limited (DMF 32542, 27830), Alembic Pharmaceuticals Limited (DMF 28057), ALIVUS LIFE SCIENCES LTD (DMF 26807), Biocon Limited (DMF 28276), Emcure Pharmaceuticals Limited (DMF 28235), HONOUR LAB LTD (DMF 28225), Intas Pharmaceuticals Ltd. (DMF 28387) and MAPRIMED SA (DMF 28322) and 10 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does Fingolimod Hydrochloride have a European Certificate of Suitability?

Yes. 15 organisations hold a valid CEP for Fingolimod Hydrochloride on the EDQM register, including MAPRIMED S.A. Buenos Aires (AR), BIOCON LIMITED Bengaluru (IN), HONOUR LAB LIMITED Hyderabad (IN), MATRIX PHARMACORP PRIVATE LIMITED Sangareddy (IN), EMCURE PHARMACEUTICALS LIMITED Pune (IN) and INTAS PHARMACEUTICALS LIMITED Ahmedabad (IN) and 9 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Fingolimod Hydrochloride?

Yes. The latest patent listed for an approved US product containing Fingolimod Hydrochloride expires 30 Sept 2032, across 17 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Fingolimod Hydrochloride supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Fingolimod Hydrochloride?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.